Terms: = Skin cancer AND WWTR1, ENSG00000018408, 25937, Q9GZV5, DKFZP586I1419
14 results:
1. NDFIP1 limits cellular TAZ accumulation via exosomal sorting to inhibit NSCLC proliferation.
Cheng Y; Lu X; Li F; Chen Z; Zhang Y; Han Q; Zeng Q; Wu T; Li Z; Lu S; Williams C; Xia W
Protein Cell; 2023 Mar; 14(2):123-136. PubMed ID: 36929005
[TBL] [Abstract] [Full Text] [Related]
2. YAP1 and wwtr1 expression inversely correlates with neuroendocrine markers in Merkel cell carcinoma.
Frost TC; Gartin AK; Liu M; Cheng J; Dharaneeswaran H; Keskin DB; Wu CJ; Giobbie-Hurder A; Thakuria M; DeCaprio JA
J Clin Invest; 2023 Mar; 133(5):. PubMed ID: 36719743
[TBL] [Abstract] [Full Text] [Related]
3. Targeting the Hippo/YAP/TAZ signalling pathway: Novel opportunities for therapeutic interventions into skin cancers.
Howard A; Bojko J; Flynn B; Bowen S; Jungwirth U; Walko G
Exp Dermatol; 2022 Oct; 31(10):1477-1499. PubMed ID: 35913427
[TBL] [Abstract] [Full Text] [Related]
4. Molecular analysis of NUT-positive poromas and porocarcinomas identifies novel break points of YAP1::NUTM1 fusions.
Snow JT; Georgantzoglou N; Green DC; Parra O; LeBlanc RE; Yan S; Sriharan A; Momtahen S; Winnick KN; Dimonitsas E; Stavrianos S; Lakiotaki E; Korkolopoulou P; Revelos K; Guo R; Linos K
J Cutan Pathol; 2022 Oct; 49(10):850-858. PubMed ID: 35665951
[TBL] [Abstract] [Full Text] [Related]
5. Fusion-positive skin/adnexal carcinomas.
Agaimy A
Genes Chromosomes Cancer; 2022 May; 61(5):274-284. PubMed ID: 35167714
[TBL] [Abstract] [Full Text] [Related]
6. Targeting the YAP/TAZ Pathway in Uveal and Conjunctival Melanoma With Verteporfin.
Brouwer NJ; Konstantinou EK; Gragoudas ES; Marinkovic M; Luyten GPM; Kim IK; Jager MJ; Vavvas DG
Invest Ophthalmol Vis Sci; 2021 Apr; 62(4):3. PubMed ID: 33798262
[TBL] [Abstract] [Full Text] [Related]
7. Case of epithelioid hemangioendothelioma occurring in the postradiation setting for breast cancer.
Hahn E; Dickson BC; Gupta AA; Nofech-Mozes S
Genes Chromosomes Cancer; 2021 Feb; 60(2):112-115. PubMed ID: 33125182
[TBL] [Abstract] [Full Text] [Related]
8. YAP/TAZ: Drivers of Tumor Growth, Metastasis, and Resistance to Therapy.
Thompson BJ
Bioessays; 2020 May; 42(5):e1900162. PubMed ID: 32128850
[TBL] [Abstract] [Full Text] [Related]
9. The Hippo pathway integrates PI3K-Akt signals with mechanical and polarity cues to control tissue growth.
Borreguero-Muñoz N; Fletcher GC; Aguilar-Aragon M; Elbediwy A; Vincent-Mistiaen ZI; Thompson BJ
PLoS Biol; 2019 Oct; 17(10):e3000509. PubMed ID: 31613895
[TBL] [Abstract] [Full Text] [Related]
10. Recurrent YAP1-MAML2 and YAP1-NUTM1 fusions in poroma and porocarcinoma.
Sekine S; Kiyono T; Ryo E; Ogawa R; Wakai S; Ichikawa H; Suzuki K; Arai S; Tsuta K; Ishida M; Sasajima Y; Goshima N; Yamazaki N; Mori T
J Clin Invest; 2019 May; 129(9):3827-3832. PubMed ID: 31145701
[TBL] [Abstract] [Full Text] [Related]
11. YAP and wwtr1: New targets for skin cancer treatment.
Andl T; Zhou L; Yang K; Kadekaro AL; Zhang Y
Cancer Lett; 2017 Jun; 396():30-41. PubMed ID: 28279717
[TBL] [Abstract] [Full Text] [Related]
12. Advances in the clinicopathological and molecular classification of cutaneous mesenchymal neoplasms.
Costigan DC; Doyle LA
Histopathology; 2016 May; 68(6):776-95. PubMed ID: 26763770
[TBL] [Abstract] [Full Text] [Related]
13. YAP immunoreactivity is directly related to pilomatrixoma size and proliferation rate.
Cappellesso R; Bellan A; Saraggi D; Salmaso R; Ventura L; Fassina A
Arch Dermatol Res; 2015 May; 307(4):379-83. PubMed ID: 25516090
[TBL] [Abstract] [Full Text] [Related]
14. CAMTA1 immunostaining is not useful in differentiating epithelioid hemangioendothelioma from its potential mimickers.
Yusıflı Z; Kösemehmetoğlu K
Turk Patoloji Derg; 2014; 30(3):159-65. PubMed ID: 25110239
[TBL] [Abstract] [Full Text] [Related]
